Amphastar Pharmaceuticals, Inc.
AMPH
Rank in Stocks
#7739
Amphastar Pharmaceuticals, Inc., established in 1996 and based in Rancho... Amphastar Pharmaceuticals, Inc., established in 1996 and based in Rancho Cucamonga, California, functions as a biopharmaceutical enterprise. The company is engaged in the creation, production, commercialization, and distribution of both generic and proprietary pharmaceutical products, which include injectables, inhalants, and intranasal formulations. Its market presence extends across the United States, China, and France. Amphastar's operations are divided into two primary segments: Finished Pharmaceutical Products and Active Pharmaceutical Ingredients (API). The company's extensive product portfolio encompasses a variety of crucial medications. These feature Primatene Mist, an over-the-counter epinephrine inhaler for the temporary alleviation of mild asthma symptoms; Enoxaparin, a low molecular weight heparin utilized for the prevention and treatment of deep vein thrombosis; and Naloxone, an essential treatment for opioid overdose. Other significant offerings include emergency Glucagon injection kits; Cortrosyn, a diagnostic agent for adrenocortical insufficiency; and Amphadase, a bovine-sourced hyaluronidase injection that aids in the absorption and dispersion of other administered drugs. Amphastar additionally supplies Epinephrine injections for severe allergic reactions; various lidocaine products (such as a jelly for urological procedures and a topical solution for other applications); Phytonadione injection (Vitamin K1) for newborns; and specialized emergency syringe products for hospital use. Furthermore, the company provides Morphine injections for patient-controlled analgesia and Lorazepam injections for surgical and medical procedures. More advanced therapeutics consist of Neostigmine methylsulfate injection to manage myasthenia gravis and reverse muscle relaxant effects, and Isoproterenol hydrochloride injection for mild or transient episodes of heart block. Beyond its finished pharmaceutical goods, Amphastar also acts as a distributor for recombinant human insulin API and porcine insulin API. The company caters to a broad spectrum of healthcare providers, including hospitals, various care facilities, clinics, and physicians' offices.
Share Price
$29.38
Last synced: 2026-11-09
Market Cap
$1.25B
Change (1 day)
3.12%
Change (1 year)
8.17%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Amphastar Pharmaceuticals, Inc. (AMPH)
Category
Healthcare
Operating Margin for Amphastar Pharmaceuticals, Inc. (AMPH)
Operating Margin as of November 2026 TTM: 15.66%
According to Amphastar Pharmaceuticals, Inc.'s latest financial reports, its current operating margin (TTM) is 15.66%. At the end of 2025 the company had an operating margin of 19.50%.
Operating Margin history for Amphastar Pharmaceuticals, Inc. from 2011 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | 15.66% | -19.69% |
| 2025 | 19.50% | -30.51% |
| 2024 | 28.06% | -8.21% |
| 2023 | 30.57% | 41.92% |
| 2022 | 21.54% | 34.96% |
| 2021 | 15.96% | 409.90% |
| 2020 | 3.13% | -31,400.00% |
| 2019 | -0.01% | -99.66% |
| 2018 | -2.93% | 691.89% |
| 2017 | -0.37% | -106.02% |
| 2016 | 6.15% | -324.45% |
| 2015 | -2.74% | -67.92% |
| 2014 | -8.54% | -212.22% |
| 2013 | 7.61% | -38.78% |
| 2012 | 12.43% | -143.86% |
| 2011 | -28.34% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 19.41% | -98.76% |
DE
|
|
| 19.68% | -98.74% |
DE
|
|
| 13.26% | -99.15% |
JP
|
|
| 17.08% | -98.91% |
CH
|
|
| 14.92% | -99.05% |
IL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Amphastar Pharmaceuticals, Inc.'s operating margin
What is Amphastar Pharmaceuticals, Inc.'s operating margin?
Amphastar Pharmaceuticals, Inc.'s operating margin is 15.66%, as of Nov 2026.
What was Amphastar Pharmaceuticals, Inc.'s operating margin in 2025?
In 2025, Amphastar Pharmaceuticals, Inc.'s operating margin was 19.50%, compared with 28.06% in 2024.
How has Amphastar Pharmaceuticals, Inc.'s operating margin changed since 2020?
From 2020 to 2025, Amphastar Pharmaceuticals, Inc.'s operating margin was highest in 2023 (30.57%) and lowest in 2020 (3.13%).
How does Amphastar Pharmaceuticals, Inc.'s operating margin compare with similar companies?
Amphastar Pharmaceuticals, Inc.'s operating margin (15.66%) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Merck KGaA, with 19.68%.